Classification and discrimination of pediatric patients undergoing open heart surgery with and without methylprednisolone treatment by cytomics
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F11%3A43905933" target="_blank" >RIV/00216208:11120/11:43905933 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1117/12.876487" target="_blank" >http://dx.doi.org/10.1117/12.876487</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1117/12.876487" target="_blank" >10.1117/12.876487</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Classification and discrimination of pediatric patients undergoing open heart surgery with and without methylprednisolone treatment by cytomics
Popis výsledku v původním jazyce
Methylprednisolone (MP) is frequently preoperatively administered in children undergoing open heart surgery. The aim of this medication is to inhibit overshooting immune responses. Earlier studies demonstrated cellular and humoral immunological changes in pediatric patients undergoing heart surgeries with and without MP administration. Here in a retrospective study we investigated the modulation of the cellular immune response by MP. The aim was to identify suitable parameters characterizing MP effectsby cluster analysis. Blood samples were analysed from two aged matched groups with surgical correction of septum defects. Group without MP treatment consisted of 10 patients; MP was administered on 21 patients (median dose: 11mg/kg) before cardiopulmonary bypass (CPB). EDTA anticoagulated blood was obtained 24 h preoperatively, after anesthesia, at CPB begin and end (CPB2), 4h, 24h, 48h after surgery, at discharge and at out-patient follow-up (8.2; 3.3-12.2 month after surgery; median an
Název v anglickém jazyce
Classification and discrimination of pediatric patients undergoing open heart surgery with and without methylprednisolone treatment by cytomics
Popis výsledku anglicky
Methylprednisolone (MP) is frequently preoperatively administered in children undergoing open heart surgery. The aim of this medication is to inhibit overshooting immune responses. Earlier studies demonstrated cellular and humoral immunological changes in pediatric patients undergoing heart surgeries with and without MP administration. Here in a retrospective study we investigated the modulation of the cellular immune response by MP. The aim was to identify suitable parameters characterizing MP effectsby cluster analysis. Blood samples were analysed from two aged matched groups with surgical correction of septum defects. Group without MP treatment consisted of 10 patients; MP was administered on 21 patients (median dose: 11mg/kg) before cardiopulmonary bypass (CPB). EDTA anticoagulated blood was obtained 24 h preoperatively, after anesthesia, at CPB begin and end (CPB2), 4h, 24h, 48h after surgery, at discharge and at out-patient follow-up (8.2; 3.3-12.2 month after surgery; median an
Klasifikace
Druh
D - Stať ve sborníku
CEP obor
FA - Kardiovaskulární nemoci včetně kardiochirurgie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
Z - Vyzkumny zamer (s odkazem do CEZ)
Ostatní
Rok uplatnění
2011
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název statě ve sborníku
Imaging, Manipulation, and Analysis of Biomolecules, Cell and Tissue IX
ISBN
978-0-81948-439-0
ISSN
0277-786X
e-ISSN
—
Počet stran výsledku
11
Strana od-do
"Art. Nr. 79021O"
Název nakladatele
International Society for Optical Engineering
Místo vydání
Bellingham
Místo konání akce
San Francisco, CA
Datum konání akce
22. 1. 2011
Typ akce podle státní příslušnosti
WRD - Celosvětová akce
Kód UT WoS článku
000297677500039